v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Sep. 30, 2025
Jun. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Mar. 31, 2026
Cash flows from operating activities              
Net loss $ (8,175) $ (8,154) $ (8,258) $ (8,078) $ (16,329) $ (16,336)  
Adjustments to reconcile net loss to net cash used in operating activities              
Depreciation         1,542 1,523  
Amortization of licensed right to use technology         102 102  
Stock-based compensation 426   1,775   1,462 3,352  
Amortization of debt discount and accretion of debt issuance costs         852 133  
Change in fair value of warrant liability (1)   1   (2) (16)  
Amortization of operating lease assets         185 217  
Paid in kind interest         840 837  
Provision for inventory losses         39 239  
Provision for bad debt         91  
Foreign currency adjustments         5 (138)  
Loss on extinguishment of debt 252     405  
Loss on disposal of fixed assets         52 57  
Loss on contract manufacturer’s inventory obsolescence         567  
Unrealized (gain)/loss on marketable securities         10 (4)  
Changes in:              
Inventory         558 492  
Accounts receivable         (455) (182)  
Other current assets and prepaid expenses         (992) 941  
Accounts payable         (20) (35)  
Accrued expenses         809 9  
Operating lease liabilities         (235) (170)  
Net cash used in operating activities         (10,514) (8,979)  
Cash flows from investing activities              
Purchase of marketable securities         (5,085) (3)  
Proceeds from sale of marketable securities         4,324 1,263  
Security deposits from lease         72  
Purchase of property and equipment         (959) (444)  
Net cash provided by (used in) investing activities         (1,648) 816  
Cash flows from financing activities              
Proceeds from issuance of common stock through at the market offerings         8,135  
Proceeds from the sale of common stock of NeuroNOS         3,981 500  
Proceeds from issuance of common stock through exercise of warrants         2,868  
Issuance of common stock warrants         90  
Issuance of common stock and pre-funded warrants through securities purchase agreement         9,109  
Proceeds from long-term loan         2,000  
Payment of loans         (343) (609)  
Net cash provided by financing activities         12,747 12,984  
Effect of exchange rate changes on cash and cash equivalents         (62) 145  
Increase in cash, cash equivalents and restricted cash         523 4,966  
Cash, cash equivalents and restricted cash at beginning of period   $ 12,362   $ 4,896 12,362 4,896 $ 4,896
Cash, cash equivalents and restricted cash at end of period $ 12,885   $ 9,862   12,885 9,862 $ 12,362
Supplemental disclosure of non-cash investing and financing activities              
Fixed assets included in accounts payable and accrued expenses         401  
Conversion of debt principal balance to equity         1,709  
Supplemental disclosure of cash flow items:              
Interest paid         237 195  
Income taxes paid